3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Recruiting
2
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
7
Peritoneal Neoplasms
4
Non-Muscle Invasive Bladder Neoplasms
4
Colorectal Neoplasms
3
Carcinoma, Transitional Cell
3
Appendiceal Neoplasms
3
Urologic Neoplasms
2
Urogenital Neoplasms
2
Stomach Neoplasms
2
Recurrence
2
Pseudomyxoma Peritonei
2
Ovarian Neoplasms
2
Neoplasms by Site
2
Neoplasms
2
Anus Neoplasms
2
Uterine Neoplasms
1
Urologic Diseases
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Sarcoma
1
Pleural Neoplasms
1
Neoplasms by Histologic Type
1
Neoplasm Metastasis
1
Necrosis
1
Mediastinal Neoplasms
1
Male Urogenital Diseases
1
Gastrointestinal Neoplasms
1
Female Urogenital Diseases
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
21
venetoclax
18
pembrolizumab
16
Dexamethasone
16
fludarabine
14
Cytarabine
13
Gemcitabine
9
pomalidomide
8
Rituximab
8
Carboplatin
8
Azacitidine
8
glofitamab
7
fludarabine phosphate
7
Lenalidomide
7
Immunotherapy, Adoptive
7
selinexor
6
Paclitaxel
6
Injections
6
Granulocyte Colony-Stimulating Factor
6
Cisplatin
6
daratumumab
5
Temozolomide
5
Oxaliplatin
5
Bevacizumab
5
zanubrutinib
4
ruxolitinib
4
Surgical Procedures, Operative
4
Nivolumab
4
Drug Therapy
4
Decitabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Recurrence
×
Mitomycin
×
Clear all
NCT06781879
2025-10-03
COBRA-NMIBC
Aarhus University Hospital
Phase 4
Recruiting
272 enrolled
NCT05874921
2025-02-28
uTRACT
UroGen Pharma Ltd.
Recruiting
400 enrolled